Rhinology

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
Vibeke Backer
DMSc, MD
Vibeke Backer

Related resources

Learning objectives

  • To understand the immunological basis of Type 2 inflammation and its role in the pathophysiology of severe, uncontrolled CRSwNP, including key cells and cytokines involved
  • To recognize the global variability in Type 2 CRSwNP prevalence and its treatment strategies across different regions
  • To identify clinical markers and patient-reported symptoms (e.g., smell loss, nasal obstruction) that guide disease severity assessment and the use of targeted therapies

Description

This video delves into the link between Type 2 inflammation and severe, uncontrolled CRSwNP. It explains the immunological basis of Type 2 disease, involving TH2 cells, eosinophils, mast cells, and cytokines like IL-4, IL-5, IL-13, TSLP, and ITE. The speaker highlights global prevalence differences, with higher rates in Western countries and urban China, and emphasizes the importance of identifying biomarkers and symptoms such as smell loss and nasal obstruction. These insights are crucial for guiding treatment decisions, as current therapies are designed to target Type 2 pathways and may not be effective for other inflammatory types.

MAT-GLB-2506245 - 1.0 - 10/2025

About this expert

Pulmonology

Vibeke Backer

DMSc, MD

Chief Respiratory Physician, Department of ENT and Centre for Physical Activity Research | Rigshospitalet, Copenhagen, Denmark

See author’s profile
Vibeke Backer